A new clinical trial at the University of Chicago is testing whether a smaller, symptom-focused surgery can help pleural mesothelioma patients maintain quality of life when tumor removal is not possible. This study looks at surgery differently compared to other trials. Rather than focusing first on complete tumor removal, it asks whether a smaller operation can safely help patients feel better and function better. The study is enrolling 30 patients with the epithelioid subtype of pleural mesothelioma. To be eligible, participants must have tumors that cannot be fully removed surgically. Patients must also have already completed chemotherapy or immunotherapy. Instead of aiming for a full resection, surgeons will perform a limited partial pleurectomy and decortication designed to ease symptoms such as pain, fluid buildup, and shortness of breath. For patients and families, the biggest takeaway is this is not a curative surgery study. Instead, it is a palliative-intent clinical trial for a specific group of patients who usually would receive medication-based therapy alone.
A surgeon at the University of Chicago claims the procedure is much different from the more aggressive mesothelioma surgeries patients may know about. The goal of traditional mesothelioma surgery is the removal of all tumors that can be seen or felt. The goal of a limited pleurectomy and decortication operation is symptom control through removal of the pleura on the chest wall and getting the lung to re-expand. The operation has two parts. Surgeons remove affected pleura from the chest wall, which may help the lung stick back to the rib cage and reduce future fluid buildup. They also remove pleura from the lung in areas where tumor is compressing it, helping the lung re-expand. The mediastinum, pericardium, and diaphragm are left untouched in this trial. That makes it different from standard or extended pleurectomy and decortication, which are usually only offered when surgeons believe all visible disease can be removed.
The research team shared that it noticed something unexpected: some patients whose tumors were not fully removed during surgery still reported fewer mesothelioma symptoms afterward, including less chest pain and shortness of breath. That pattern made them wonder whether intentional partial removal could help patients feel better without trying to eliminate the tumors entirely. They wanted to find out if using surgery could help people live comfortably for a longer time. The question is especially important for patients with unresectable pleural mesothelioma, who today are generally treated with systemic therapy alone. The team wanted to study whether a limited surgery could work with chemotherapy, immunotherapy, or other systemic treatments rather than replace them.
The best candidates for this trial are patients with epithelioid pleural mesothelioma. Their disease must not have spread beyond the chest but must still be ineligible for full resection because of the amount or location of disease. That criteria may include patients with significant diaphragm or mediastinal involvement, where surgeons are unlikely to achieve a complete resection. The study may be especially appealing to patients who are focused on improving their quality of life. Patients with biphasic or sarcomatoid subtypes of mesothelioma are not eligible. Neither are patients whose cancer has spread beyond the chest.
The study’s main goal is to see whether partial pleurectomy can help control symptoms and preserve quality of life. Researchers will also track complications, length of hospital stay, how soon patients can resume systemic therapy, and survival. It is still a major surgery, even if it is smaller in scope than traditional mesothelioma operations. For unresectable patients, joining the clinical trial means undergoing an operation they otherwise would not have had. For borderline resectable patients, it means not attempting a full resection. This is a palliative-intent, symptom-focused surgical study for a very specific group of patients, it is not an attempt at curative surgery. Now more than ever, patients and providers are focused on quality of life. It is now the right time to test the approach because palliative care and quality of life have become a bigger focus in cancer care, while mesothelioma surgery has become safer and better tolerated. If the study shows a meaningful quality-of-life benefit, it could lead to a larger randomized trial. This could potentially open surgical options to mesothelioma patients who previously were not considered candidates. Patients interested in the study will undergo mesothelioma biopsy confirmation, imaging, pulmonary functional testing, lab work, and multidisciplinary review. The hospital must also accept the patient’s insurance, and the surgery must be billed through standard care.
Skip to content